Rocklatan and Rhopressa brought in sales of around $112 million in 2021, up a third on the prior year, and according to Aerie, should reach $130-$140 million this year.

Throughout his investment career, Dr. Cunningham has led or co-led financings that contributed to the FDA approval of ten therapeutics, including ophthalmic treatments such as Xiidra®, Rhopressa ...